Oxford Vacmedix receives approval for its first-in-human study of OVM-200 cancer vaccine Aug. 12, 2021
SAB-185 potently neutralizes delta and lambda SARS-CoV-2 variants in nonclinical studies Aug. 12, 2021
Positive interim analysis data from phase II/III study of plonmarlimab in severe COVID-19 Aug. 12, 2021
RSS